EU PERSPECTIVES - It can save young lives but it is not attractive enough for investors. That is the cruel economics of childhood cancer treatment. Léonor, a ten-year-old cancer survivor, asks Europe to change that. Read more

EU PERSPECTIVES - Europe's top life sciences investors have welcomed the EU's new €5bn Scaleup Europe Fund. One of its own backers, Novo Holdings, has just put €500m into it. Yet the same investors told EU Perspectives the fund will barely touch their sector's real funding problem. Read more

EURACTIV - Hungarian universities remain barred from the EU's flagship Horizon research programme, it has no national dementia plan, and the diagnostic infrastructure the new drugs depend on barely exists. Read more

EU PERSPECTIVES - Tariff threats are working, the president declared, crediting them with forcing pharma companies and foreign governments to accept his most-favoured-nation pricing plan. Instead of driving prices sharply lower in the US, however, it could push them up for everyone else. Read more

EU PERSPECTIVES - A mother who survives childbirth. A child who reaches their fifth birthday. This is what Dr Hans Kluge says his campaign for the world's top health job comes down to. The doctor who once treated tuberculosis in Siberian prisons is now Belgium's WHO candidate, backed by Prime Minister Bart De Wever as "someone who...

EU PERSPECTIVES - People in the Netherlands, Greece, and Italy are dying form West Nile virus infection. Europe has no specific treatment against it, Brussels has confirmed. Read more

EURACTIV - Over the next decade, a wave of biologic medicines will lose patent protection in Europe, but unlike the past ten years, biosimilar competition and the savings and access it brought are no longer guaranteed to follow. Read more

EU PERSPECTIVES - The biggest overhaul of Europe's pharmaceutical law in two decades is to arrive this autumn, with a two-year transition. Lawyer Hein van den Bos explains to EU Perspectives what changes, what the debate missed, and why anything now in development is already affected. Read more

EURACTIV - Belgium does not spend unusually little on medicines compared with its larger neighbours. It spends the money badly, argues Professor Walter Van Dyck. The economist says Belgium cuts prices hard to stay within a tight budget today, then pays later in lost innovation. Read more

EU PERSPECTIVES - New medicines are reaching Europe later than the US. A recent study says two separate policies are to blame, and that the damage is the worst when they meet. Read more